|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US6492107B1
(en)
|
1986-11-20 |
2002-12-10 |
Stuart Kauffman |
Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
|
|
GB2183661B
(en)
|
1985-03-30 |
1989-06-28 |
Marc Ballivet |
Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
|
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
EP0279582A3
(en)
|
1987-02-17 |
1989-10-18 |
Pharming B.V. |
Dna sequences to target proteins to the mammary gland for efficient secretion
|
|
US4873316A
(en)
|
1987-06-23 |
1989-10-10 |
Biogen, Inc. |
Isolation of exogenous recombinant proteins from the milk of transgenic mammals
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8725529D0
(en)
|
1987-10-30 |
1987-12-02 |
Delta Biotechnology Ltd |
Polypeptides
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5686073A
(en)
|
1990-05-23 |
1997-11-11 |
The University Of Iowa Research Foundation |
Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
|
|
US5543293A
(en)
|
1990-06-11 |
1996-08-06 |
Nexstar Pharmaceuticals, Inc. |
DNA ligands of thrombin
|
|
US5503978A
(en)
|
1990-06-11 |
1996-04-02 |
University Research Corporation |
Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
|
|
US5580737A
(en)
|
1990-06-11 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
|
|
EP0542810A1
(en)
|
1990-08-02 |
1993-05-26 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
CA2114015C
(en)
|
1991-07-25 |
2002-12-10 |
Roland A. Newman |
Recombinant antibodies for human therapy
|
|
WO1993006126A1
(en)
|
1991-09-13 |
1993-04-01 |
Chiron Corporation |
Immunoreactive hepatitis c virus polypeptide compositions
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5455338A
(en)
|
1993-11-05 |
1995-10-03 |
Zymogenetics, Inc. |
DNA encoding novel human kunitz-type inhibitors and methods relating thereto
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
US5631146A
(en)
|
1995-01-19 |
1997-05-20 |
The General Hospital Corporation |
DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
|
|
US20050131222A1
(en)
|
1995-04-21 |
2005-06-16 |
Human Genome Sciences, Inc. |
Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
US6709659B1
(en)
|
1996-08-02 |
2004-03-23 |
Zymogenetics, Inc. |
Antibodies that bind testis-specific insulin homolog polypeptides
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
WO1999055369A1
(en)
|
1998-04-28 |
1999-11-04 |
Smithkline Beecham Corporation |
Monoclonal antibodies with reduced immunogenicity
|
|
US6322788B1
(en)
|
1998-08-20 |
2001-11-27 |
Stanley Arthur Kim |
Anti-bacterial antibodies and methods of use
|
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
US6303321B1
(en)
|
1999-02-11 |
2001-10-16 |
North Shore-Long Island Jewish Research Institute |
Methods for diagnosing sepsis
|
|
US6939545B2
(en)
|
1999-04-28 |
2005-09-06 |
Genetics Institute, Llc |
Composition and method for treating inflammatory disorders
|
|
US20020042386A1
(en)
|
2000-01-31 |
2002-04-11 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
|
JP2004509617A
(ja)
|
2000-09-08 |
2004-04-02 |
シェーリング コーポレイション |
哺乳動物遺伝子；関連試薬および方法
|
|
WO2004001058A2
(en)
|
2001-05-04 |
2003-12-31 |
Paratek Pharmaceuticals, Inc. |
Transcription factor modulating compounds and methods of use thereof
|
|
EP1392844A4
(en)
|
2001-05-15 |
2006-09-06 |
Long Island Jewish Res Inst |
USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
|
|
JP4511173B2
(ja)
|
2001-08-24 |
2010-07-28 |
マイジェニックス インコーポレイテッド |
抗菌性および抗炎症性ペプチド
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
US20030099602A1
(en)
|
2001-10-25 |
2003-05-29 |
Levin Gilbert V. |
D-tagatose as an anti-biofilm agent
|
|
EP1524991A1
(en)
|
2002-08-02 |
2005-04-27 |
GlaxoSmithKline Biologicals S.A. |
Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
|
|
CA2506328A1
(en)
|
2002-11-20 |
2004-06-03 |
Critical Therapeutics, Inc. |
Use of hmgb fragments as anti-inflammatory agents
|
|
JP2006506441A
(ja)
|
2002-11-20 |
2006-02-23 |
ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト |
免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
|
|
EP1579221A2
(de)
|
2003-01-03 |
2005-09-28 |
Alcedo Biotech GmbH |
Verwendungen von hmgb, hmgn, hmga proteinen
|
|
US7297340B2
(en)
|
2003-01-07 |
2007-11-20 |
University Of Iowa Research Foundation |
Vaccine and method for preventing biofilm formation
|
|
EP1592707A2
(en)
|
2003-02-14 |
2005-11-09 |
Fondazione Centro San Raffaele Del Monte Tabor |
Hmgb1 modulator binding domain
|
|
CA2796381A1
(en)
|
2003-03-06 |
2004-09-16 |
Children's Hospital, Inc. |
Genes of an otitis media isolate of nontypeable haemophilus influenzae
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
AU2005226420A1
(en)
|
2004-03-26 |
2005-10-06 |
Locomogene, Inc. |
Decoy nucleic acid to synoviolin gene promoter
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
WO2006083301A2
(en)
|
2004-06-17 |
2006-08-10 |
Medimmune, Inc. |
Immunogenic compositions comprising hmgb1 polypeptides
|
|
US20060030539A1
(en)
|
2004-08-06 |
2006-02-09 |
National Jewish Medical And Research Center |
Product and process for inhibition of biofilm development
|
|
US7585504B2
(en)
|
2004-10-22 |
2009-09-08 |
Medimmune, Llc |
High affinity antibodies against HMGB1 and methods of use thereof
|
|
AU2005325801A1
(en)
|
2005-01-31 |
2006-08-03 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
US7119179B1
(en)
|
2005-03-21 |
2006-10-10 |
Los Alamos National Security, Llc |
Preparation of high nitrogen compound and materials therefrom
|
|
US20060228384A1
(en)
|
2005-04-06 |
2006-10-12 |
Sequoia Sciences, Inc. |
Control of biofilm with a biofilm inhibitor
|
|
WO2006114805A2
(en)
|
2005-04-28 |
2006-11-02 |
Fondazione Centro San Raffaele Del Monte Tabor |
Use of hmgb2 and hmgb3 proteins for medical applications
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
CA2642754A1
(en)
|
2006-02-13 |
2007-08-23 |
Trustees Of Boston University |
Compositions and methods for antibiotic potentiation and drug discovery
|
|
PL2061886T3
(pl)
|
2006-08-21 |
2014-10-31 |
Univ British Columbia |
Małe kationowe peptydy immunomodulujące
|
|
EP1980269A1
(en)
|
2007-04-13 |
2008-10-15 |
Katholieke Universiteit Leuven |
Prevention of staphylococcus biofilm formation
|
|
MX2012010793A
(es)
|
2010-03-29 |
2013-05-09 |
Univ Southern California |
Composiciones y metodos para la eliminacion de biopeliculas.
|
|
EP2613797B1
(en)
*
|
2010-09-09 |
2015-11-04 |
University Of Southern California |
Compositions and methods for the removal of biofilms
|
|
WO2014016417A1
(en)
|
2012-07-26 |
2014-01-30 |
Ospedale San Raffaele Srl |
Hmgb1 variants and uses thereof
|
|
CA2915210A1
(en)
|
2013-06-13 |
2014-12-18 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for the treatment of burkholderia infections
|
|
US9745366B2
(en)
|
2013-09-23 |
2017-08-29 |
University Of Southern California |
Compositions and methods for the prevention of microbial infections
|
|
GB201508337D0
(en)
|
2015-05-15 |
2015-06-24 |
Hmgbiotech S R L |
Novel peptides
|
|
AU2018236271B2
(en)
*
|
2017-03-15 |
2023-12-21 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
|
US20210139610A1
(en)
|
2018-06-29 |
2021-05-13 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for mediating eps
|
|
SG11202103001PA
(en)
|
2018-10-05 |
2021-04-29 |
Res Inst Nationwide Childrens Hospital |
Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
|